Mac Rabonik Plus Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Rabeprazole 40 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and dyspepsia. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in the parietal cells of the stomach, providing effective relief from acid-related conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. The sustained-release formulation of Mac Rabonik Plus ensures prolonged therapeutic action, improving patient compliance and symptom control. This combination is particularly beneficial in patients presenting with functional dyspepsia accompanied by acid-related mucosal damage or in cases where enhanced gastric motility and acid suppression are concurrently required. Mac Rabonik Plus Capsule SR should be administered under medical supervision, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with hypersensitivity to either component, and monitoring is recommended during prolonged therapy to detect potential adverse effects.